Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Identifieur interne : 000731 ( PubMed/Corpus ); précédent : 000730; suivant : 000732Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Auteurs : Rishi Puri ; Christie M. Ballantyne ; Ron C. Hoogeveen ; Mingyuan Shao ; Philip Barter ; Peter Libby ; M John Chapman ; Raimund Erbel ; Benoit J. Arsenault ; Joel S. Raichlen ; Steven E. Nissen ; Stephen J. NichollsSource :
- Atherosclerosis [ 1879-1484 ] ; 2017.
Abstract
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma volume following long-term maximally-intensive statin therapy in coronary artery disease patients.
DOI: 10.1016/j.atherosclerosis.2017.06.026
PubMed: 28641153
Links to Exploration step
pubmed:28641153Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.</title><author><name sortKey="Puri, Rishi" sort="Puri, Rishi" uniqKey="Puri R" first="Rishi" last="Puri">Rishi Puri</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States; Quebec Heart & Lung Institute, Quebec City, Canada; Department of Medicine, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name><affiliation><nlm:affiliation>Section of Cardiovascular Research, Baylor College of Medicine, The Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Hoogeveen, Ron C" sort="Hoogeveen, Ron C" uniqKey="Hoogeveen R" first="Ron C" last="Hoogeveen">Ron C. Hoogeveen</name><affiliation><nlm:affiliation>Section of Cardiovascular Research, Baylor College of Medicine, The Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Shao, Mingyuan" sort="Shao, Mingyuan" uniqKey="Shao M" first="Mingyuan" last="Shao">Mingyuan Shao</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Barter, Philip" sort="Barter, Philip" uniqKey="Barter P" first="Philip" last="Barter">Philip Barter</name><affiliation><nlm:affiliation>Centre for Vascular Research, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Libby, Peter" sort="Libby, Peter" uniqKey="Libby P" first="Peter" last="Libby">Peter Libby</name><affiliation><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name><affiliation><nlm:affiliation>INSERM Dyslipidaemia and Atherosclerosis Research Unit, Pitié-Salpetriere University Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Erbel, Raimund" sort="Erbel, Raimund" uniqKey="Erbel R" first="Raimund" last="Erbel">Raimund Erbel</name><affiliation><nlm:affiliation>West German Heart Center, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Arsenault, Benoit J" sort="Arsenault, Benoit J" uniqKey="Arsenault B" first="Benoit J" last="Arsenault">Benoit J. Arsenault</name><affiliation><nlm:affiliation>Quebec Heart & Lung Institute, Quebec City, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Raichlen, Joel S" sort="Raichlen, Joel S" uniqKey="Raichlen J" first="Joel S" last="Raichlen">Joel S. Raichlen</name><affiliation><nlm:affiliation>AstraZeneca, Gaithersburg, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J" last="Nicholls">Stephen J. Nicholls</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States; Department of Medicine, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, Adelaide, Australia. Electronic address: stephen.nicholls@sahmri.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28641153</idno><idno type="pmid">28641153</idno><idno type="doi">10.1016/j.atherosclerosis.2017.06.026</idno><idno type="wicri:Area/PubMed/Corpus">000731</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000731</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.</title><author><name sortKey="Puri, Rishi" sort="Puri, Rishi" uniqKey="Puri R" first="Rishi" last="Puri">Rishi Puri</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States; Quebec Heart & Lung Institute, Quebec City, Canada; Department of Medicine, University of Adelaide, Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name><affiliation><nlm:affiliation>Section of Cardiovascular Research, Baylor College of Medicine, The Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Hoogeveen, Ron C" sort="Hoogeveen, Ron C" uniqKey="Hoogeveen R" first="Ron C" last="Hoogeveen">Ron C. Hoogeveen</name><affiliation><nlm:affiliation>Section of Cardiovascular Research, Baylor College of Medicine, The Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Shao, Mingyuan" sort="Shao, Mingyuan" uniqKey="Shao M" first="Mingyuan" last="Shao">Mingyuan Shao</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Barter, Philip" sort="Barter, Philip" uniqKey="Barter P" first="Philip" last="Barter">Philip Barter</name><affiliation><nlm:affiliation>Centre for Vascular Research, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Libby, Peter" sort="Libby, Peter" uniqKey="Libby P" first="Peter" last="Libby">Peter Libby</name><affiliation><nlm:affiliation>Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name><affiliation><nlm:affiliation>INSERM Dyslipidaemia and Atherosclerosis Research Unit, Pitié-Salpetriere University Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Erbel, Raimund" sort="Erbel, Raimund" uniqKey="Erbel R" first="Raimund" last="Erbel">Raimund Erbel</name><affiliation><nlm:affiliation>West German Heart Center, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Arsenault, Benoit J" sort="Arsenault, Benoit J" uniqKey="Arsenault B" first="Benoit J" last="Arsenault">Benoit J. Arsenault</name><affiliation><nlm:affiliation>Quebec Heart & Lung Institute, Quebec City, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Raichlen, Joel S" sort="Raichlen, Joel S" uniqKey="Raichlen J" first="Joel S" last="Raichlen">Joel S. Raichlen</name><affiliation><nlm:affiliation>AstraZeneca, Gaithersburg, MD, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States.</nlm:affiliation></affiliation></author><author><name sortKey="Nicholls, Stephen J" sort="Nicholls, Stephen J" uniqKey="Nicholls S" first="Stephen J" last="Nicholls">Stephen J. Nicholls</name><affiliation><nlm:affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States; Department of Medicine, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, Adelaide, Australia. Electronic address: stephen.nicholls@sahmri.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Atherosclerosis</title><idno type="eISSN">1879-1484</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma volume following long-term maximally-intensive statin therapy in coronary artery disease patients.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28641153</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>22</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1484</ISSN><JournalIssue CitedMedium="Internet"><Volume>263</Volume><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Atherosclerosis</Title><ISOAbbreviation>Atherosclerosis</ISOAbbreviation></Journal><ArticleTitle>Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.</ArticleTitle><Pagination><MedlinePgn>137-144</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0021-9150(17)30275-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.atherosclerosis.2017.06.026</ELocationID><Abstract><AbstractText Label="BACKGROUND & AIMS" NlmCategory="OBJECTIVE">Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma volume following long-term maximally-intensive statin therapy in coronary artery disease patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Study of coronary atheroma by intravascular ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. Baseline and follow-up Lp(a) levels were measured in 915 of the 1039 SATURN participants, and were correlated with changes in percent atheroma volume (ΔPAV).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean age was 57.7 ± 8.6 years, 74% were men, 96% were Caucasian, with statin use prior to study enrolment occurring in 59.3% of participants. Baseline [median (IQR)] LDL-cholesterol (LDL-C) and measured Lp(a) levels (mg/dL) were 114 (99, 137) and 17.4 (7.6, 52.9) respectively; follow-up measures were 60 (47, 77), and 16.5 (6.7, 57.7) (change from baseline: p < 0.001, p = 0.31 respectively). At baseline, there were 676 patients with Lp(a) levels <50 mg/dL [median Lp(a) of 10.9 mg/dL], and 239 patients with Lp(a) levels ≥ 50 mg/dL [median Lp(a) of 83.2 mg/dL]. Quartiles of baseline and follow-up Lp(a) did not associate with ΔPAV. Irrespective of the achieved LDL-C ( 50 mg/dL.</AbstractText> <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In coronary artery disease patients prescribed long-term maximally intensive statin therapy with low on-treatment LDL-C levels, measured Lp(a) levels (predominantly below the 50 mg/dL threshold) do not associate with coronary atheroma progression. Alternative biomarkers may thus associate with residual cardiovascular risk in such patients.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puri</LastName><ForeName>Rishi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States; Quebec Heart & Lung Institute, Quebec City, Canada; Department of Medicine, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballantyne</LastName><ForeName>Christie M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Research, Baylor College of Medicine, The Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoogeveen</LastName><ForeName>Ron C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Research, Baylor College of Medicine, The Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Mingyuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barter</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Vascular Research, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libby</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>M John</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>INSERM Dyslipidaemia and Atherosclerosis Research Unit, Pitié-Salpetriere University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erbel</LastName><ForeName>Raimund</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>West German Heart Center, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arsenault</LastName><ForeName>Benoit J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Quebec Heart & Lung Institute, Quebec City, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raichlen</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>AstraZeneca, Gaithersburg, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nissen</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholls</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Coordinating Center for Clinical Research (C5R), Cleveland Clinic, Cleveland, OH, United States; Department of Medicine, University of Adelaide, Adelaide, Australia; South Australian Health and Medical Research Institute, Adelaide, Australia. Electronic address: stephen.nicholls@sahmri.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Atherosclerosis</MedlineTA><NlmUniqueID>0242543</NlmUniqueID><ISSNLinking>0021-9150</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atherosclerosis</Keyword><Keyword MajorTopicYN="N">IVUS</Keyword><Keyword MajorTopicYN="N">Lipoprotein(a)</Keyword><Keyword MajorTopicYN="N">Residual risk</Keyword><Keyword MajorTopicYN="N">Statins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>06</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28641153</ArticleId><ArticleId IdType="pii">S0021-9150(17)30275-7</ArticleId><ArticleId IdType="doi">10.1016/j.atherosclerosis.2017.06.026</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000731 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000731 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28641153
|texte= Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28641153" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |